The RxView Blog

Real world data, analytics, and insights for healthcare decision makers

Advera Health Analytics, Inc.

Shadow Pricing, Highway Robbery, and the Price of Drugs

Posted by Brian Overstreet on May 15, 2015

It’s often difficult to pinpoint the moment a revolution starts, but when it comes to the issue of drug pricing it’s quite possible that we’ll look back at December 6, 2013 as the day that everything changed.

That was the day that Gilead’s Sovaldi was approved for sale by the FDA.  Sovaldi’s launch – and its $84,000 price tag – set off a tsunami of media attention on the issue of medication costs.  Never mind that Sovaldi has an incredible cure rate, all of the attention fell squarely on it $84,000 price tag.

Read More

Topics: Drug Safety, Big Pharma, cost review

How New-Agers and Hipsters are Popularizing Drug Safety

Posted by Andrea Demakas on September 5, 2014

I’m not usually one to keep up with the latest trends, but I have been noticing how some of the fads from the past couple of years could actually make drug safety seem cool to the general public. Yes, I said it. We’re probably going to be extremely popular after this blog post goes out.

Hipsters are like cool nerds, with hats and extravagant mustaches. New-agers are like health nuts, with the addition of conspiracy theories and healing crystals. Are you starting to see where I am going with this? It’s okay if you don’t -- some people may think I’m making quite a leap. Let me explain.

Read More

Topics: Drug Safety, Big Pharma, Pharmacovigilance

3 Drug Safety Facts that Big Pharma Doesn’t Want You to Know

Posted by Jim Davis on March 13, 2014

Drug Safety FactsI started with AdverseEvents just about 1 year ago. Prior to entering the crazy world of drug safety, I spent my time on the money making side of the business; Commercializing data and analytics to help pharmaceutical and biotech manufacturers get their drugs to market and sell them effectively and help investors find the best opportunities in the crowded and competitive industry.

It was rewarding to be a small part of the grueling process of drug development. It also gave me the opportunity to learn a lot about what makes a drug successful beyond just being proven efficacious and safe in clinical trials.

Read More

Topics: Drug Safety, Big Pharma, Managed Care Organization

Subscribe to Email Updates